Loading...
Children who receive single-dose nevirapine at birth may have better rates of virologic suppression with subsequent antiretroviral regimens that contain lopinavir/ritonavir than with those that contain nevirapine, according to a recent press release from the National Institute of Allergy and Infectious Diseases. This finding emerged during an interim analysis of the P1060 trial in Asia and Africa and is consistent with current WHO recommendations regarding antiretroviral regimens in children previously exposed to nevirapine.
Ritonavir-boosted lopinavir proves superior to nevirapine in HIV-infected infants who received single-dose nevirapine at birth [press release]. Bethesda, MD: National Institute of Allergy and Infectious Diseases; May 6, 2009. (http://www3.niaid.nih.gov/news/newsreleases/2009/P1060.htm)